Literature DB >> 7591102

Trypanosoma cruzi immunosuppressive factor decreases the interleukin-2 mRNA level in cultured normal activated human lymphocytes.

S Majumder1, F Kierszenbaum.   

Abstract

We show here that the marked inhibition of interleukin-2 production seen in hosts acutely infected with Trypanosoma cruzi can be reproduced in vitro by adding a T. cruzi suspension filtrate to cultures of activated human peripheral blood mononuclear cells. This effect was not due to an accelerated decay of interleukin-2 mRNA and appeared to be selective since the levels of other mRNA molecules relevant to lymphocyte activation were not noticeably decreased. The use of normal lymphoid cells in this in vitro system makes it possible to examine the mechanisms used by T. cruzi to induce abnormalities in lymphocyte functions that also occur in infected hosts.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7591102      PMCID: PMC173651          DOI: 10.1128/iai.63.11.4546-4549.1995

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  15 in total

1.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

2.  Trypanosomal immunosuppressive factor: a secretion product(s) of Trypanosoma cruzi that inhibits proliferation and IL-2 receptor expression by activated human peripheral blood mononuclear cells.

Authors:  F Kierszenbaum; W R Cuna; L A Beltz; M B Sztein
Journal:  J Immunol       Date:  1990-05-15       Impact factor: 5.422

3.  Suppression of human lymphocyte responses by Trypanosoma cruzi.

Authors:  L A Beltz; F Kierszenbaum
Journal:  Immunology       Date:  1987-02       Impact factor: 7.397

4.  Selective suppressive effects of Trypanosoma cruzi infection on IL-2, c-myc, and c-fos gene expression.

Authors:  L Soong; R L Tarleton
Journal:  J Immunol       Date:  1992-09-15       Impact factor: 5.422

5.  Changes in Trypanosoma cruzi infectivity by treatments that affect calcium ion levels.

Authors:  M A Yakubu; S Majumder; F Kierszenbaum
Journal:  Mol Biochem Parasitol       Date:  1994-07       Impact factor: 1.759

6.  Mechanisms regulating the level of IL-2 mRNA in T lymphocytes.

Authors:  J Shaw; K Meerovitch; R C Bleackley; V Paetkau
Journal:  J Immunol       Date:  1988-04-01       Impact factor: 5.422

7.  Inhibition of mitogen-induced proliferation of mouse T and B lymphocytes by bloodstream forms of Trypanosoma cruzi.

Authors:  J R Maleckar; F Kierszenbaum
Journal:  J Immunol       Date:  1983-02       Impact factor: 5.422

8.  Interleukin 2 enhances specific and nonspecific immune responses in experimental Chagas' disease.

Authors:  L Choromanski; R E Kuhn
Journal:  Infect Immun       Date:  1985-11       Impact factor: 3.441

9.  Use of parasite antigens and interleukin-2 to enhance suppressed immune responses during Trypanosoma cruzi infection in mice.

Authors:  L Choromanski; R E Kuhn
Journal:  Infect Immun       Date:  1987-02       Impact factor: 3.441

10.  Human T cell activation. III. Rapid induction of a phosphorylated 28 kD/32 kD disulfide-linked early activation antigen (EA 1) by 12-o-tetradecanoyl phorbol-13-acetate, mitogens, and antigens.

Authors:  T Hara; L K Jung; J M Bjorndahl; S M Fu
Journal:  J Exp Med       Date:  1986-12-01       Impact factor: 14.307

View more
  2 in total

1.  Decreased level of antibodies and cardiac involvement in patients with chronic Chagas heart disease vaccinated with BCG.

Authors:  Miguel Hernán Vicco; Iván Alejandro Bontempi; Luz Rodeles; Agustina Yodice; Iván Sergio Marcipar; Oscar Bottasso
Journal:  Med Microbiol Immunol       Date:  2013-12-29       Impact factor: 3.402

2.  A soluble factor from Trypanosoma cruzi inhibits transforming growth factor-ß-induced MAP kinase activation and gene expression in dermal fibroblasts.

Authors:  G Adam Mott; Jaime A Costales; Barbara A Burleigh
Journal:  PLoS One       Date:  2011-09-08       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.